RANCHO CORDOVA, Calif.,
Sept. 14 /PRNewswire-FirstCall/ --
ThermoGenesis Corp. (Nasdaq: KOOLD), a leading supplier of
innovative products and services that process and store adult stem
cells, said today that revenues for the fourth quarter of fiscal
2010 were $7.2 million versus
revenues of $4.0 million for the same
quarter a year ago. Revenues in the third quarter of fiscal 2010
were $4.8 million.
The Company recorded disposable revenues of $4.8 million in the fourth quarter of fiscal 2010
compared to disposable revenues of $2.2
million in the fourth quarter a year ago and $3.0 million in the prior quarter.
For the quarter ended June 30,
2010, the Company reported a net loss of $171,000, or $0.01
per share, versus a net loss of $3.1
million, or $0.22 per share,
in the fourth quarter a year ago. The results for the fourth
quarter of fiscal 2010 compared to a net loss of $1.4 million, or $0.10 per share, in the third quarter of fiscal
2010. The per share results for all periods have been adjusted to
reflect the impact of the Company's reverse stock split that
occurred at the close of business on August
26, 2010.
For all of fiscal 2010, ThermoGenesis reported revenues of
$23.1 million, an increase of 17
percent versus revenues of $19.8
million in fiscal 2009. Disposable revenues for fiscal 2010
were $14.3 million versus disposable
revenues of $10.6 million in fiscal
2009, an increase of 35 percent. The Company reported a net loss of
$5.2 million, or $0.37 per share, in fiscal 2010, versus a net
loss of $8.6 million or $0.61 per share, in fiscal 2009. The
Company ended fiscal 2010 with $10.7
million in cash and short-term investments versus
$10.1 million at the end of the third
quarter of fiscal 2010 and $15.6
million at the end of fiscal 2009.
"ThermoGenesis ended fiscal 2010 with an excellent quarter,
highlighted by a 78 percent increase over revenues from the same
quarter one year ago, as we experienced strong sales of our AXP®
AutoXpress™ (AXP) System bag sets and strong activity for our
BioArchive® Systems. This revenue growth, combined with our success
at managing operating expenses, enabled us to reduce our net loss
quarter-over quarter by approximately $3
million and achieve near break even," said J. Melville Engle, Chief Executive Officer of
ThermoGenesis.
"Our results for all of fiscal 2010 reflect a 17 percent growth
in revenues and a 39 percent reduction in our net loss
year-over-year. We generated double digit growth in key geographies
and, at the same time, we realized meaningful improvement in gross
margins as disposable revenues were 62 percent of total revenues
versus 54 percent a year ago.
"We ended fiscal 2010 with a number of new distribution
agreements in place that will drive our penetration of new
geographies, such as Asia, and
into expanded clinical indications, including cardiac, during
fiscal 2011. In addition, we have a new second-source supplier
ramped to full production, which will enable us to meet increased
demand for our AXP bag sets during the year."
Engle said two key initiatives for the Company during fiscal
2011 include the initiation of new product use studies designed to
demonstrate the efficacy of its bone marrow offerings, the MXP™
MarrowXpress® and Res-Q™ 60 BMC (Res-Q) Systems, and continued
product innovation. "We have several bone marrow product studies
planned or underway, and data regarding the successful use of these
products were presented at this week's International Stem Cell
Therapy European meeting," he said. "Secondly, we will be investing
in the cell separation arena by adding to our device and disposable
product portfolios, especially in the field of bone marrow
concentration," he continued.
With respect to the financial outlook for fiscal 2011, Engle
commented, "We expect to experience a double digit sales increase
year-over-year, with growth in both our cord blood and bone marrow
product lines. We also expect steady improvement in our gross
margins and continued leverage of our operating expenses. In
combination, these trends should result in a profit for the year,
with increasing profit by quarter."
Engle continued, "With respect to the first quarter of fiscal
2011, we will record two non-recurring charges. These charges are
expected to total approximately $200,000 and include the severance and
restructuring costs associated with our July
1, 2010 lay-off and an early termination fee for a facility
lease we are vacating. These two actions are part of our overall
cost reduction program. Net of these one-time charges, we expect to
be profitable for the first fiscal quarter."
Company's Conference Call and Webcast
Management will host a conference call today at 2:00 PM Pacific (5
PM Eastern) to review the fiscal 2010 fourth quarter and
full year results.
Conference call
details:
|
|
Dial-in (U.S.):
|
1-800-860-2442
|
|
Dial-in
(International):
|
1-412-858-4600
|
|
Conference Name:
|
"ThermoGenesis"
|
|
|
|
To listen to the audio webcast of the call during or after the
event, please visit
http://www.thermogenesis.com/investors-webcasts-and-calls.aspx
An audio replay of the conference call will be available
beginning approximately two hours after completion of the call for
the following five business days
To access the
replay:
|
|
Access number (U.S.):
|
1-877-344-7529
|
|
Access number
(Internationally):
|
1-412-317-0088
|
|
Conference ID#:
|
385107
|
|
|
|
|
|
THERMOGENESIS
CORP.
Condensed Consolidated Balance
Sheets
(Unaudited)
|
|
|
|
|
|
June 30,
|
|
June 30,
|
|
|
2010
|
|
2009
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
Current assets:
|
|
|
|
|
Cash and cash
equivalents
|
$10,731,000
|
|
$6,655,000
|
|
Short term
investments
|
--
|
|
8,976,000
|
|
Accounts receivable,
net
|
6,095,000
|
|
4,235,000
|
|
Inventory
|
5,034,000
|
|
5,233,000
|
|
Other current assets
|
301,000
|
|
662,000
|
|
|
|
|
|
|
Total current assets
|
22,161,000
|
|
25,761,000
|
|
|
|
|
|
|
Equipment, net
|
1,701,000
|
|
1,784,000
|
|
|
|
|
|
|
Other assets
|
168,000
|
|
110,000
|
|
|
$24,030,000
|
|
$27,655,000
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
Accounts payable
|
$2,383,000
|
|
$1,781,000
|
|
Other current
liabilities
|
$3,191,000
|
|
3,057,000
|
|
|
|
|
|
|
Total current
liabilities
|
5,574,000
|
|
4,838,000
|
|
|
|
|
|
|
Long-term liabilities
|
677,000
|
|
363,000
|
|
|
|
|
|
|
Stockholders' equity
|
17,779,000
|
|
22,454,000
|
|
|
|
|
|
|
|
$24,030,000
|
|
$27,655,000
|
|
|
|
|
|
|
|
|
|
THERMOGENESIS
CORP.
Condensed Consolidated
Statements of Operations
(Unaudited)
|
|
|
|
|
|
|
|
Three Months Ended
June 30,
|
|
Years Ended
June 30,
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
2009
|
|
2010
|
|
2009
|
|
Net revenues
|
$7,176,000
|
|
$4,023,000
|
|
$23,088,000
|
|
$19,799,000
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
4,700,000
|
|
3,617,000
|
|
15,643,000
|
|
14,106,000
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
2,476,000
|
|
406,000
|
|
7,445,000
|
|
5,693,000
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
Selling, general and
administrative
|
1,711,000
|
|
2,212,000
|
|
7,686,000
|
|
9,249,000
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
939,000
|
|
1,306,000
|
|
5,013,000
|
|
5,222,000
|
|
|
|
|
|
|
|
|
|
|
Total operating
expenses
|
2,650,000
|
|
3,518,000
|
|
12,699,000
|
|
14,471,000
|
|
|
|
|
|
|
|
|
|
|
Interest and other income,
net
|
3,000
|
|
28,000
|
|
61,000
|
|
228,000
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
($171,000)
|
|
($3,084,000)
|
|
($5,193,000)
|
|
($8,550,000)
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss
per
common share
|
($0.01)
|
|
($0.22)
|
|
($0.37)
|
|
($0.61)
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing per
share
data
|
14,023,240
|
|
14,023,240
|
|
14,023,240
|
|
14,015,115
|
|
|
|
|
|
|
|
|
|
|
|
THERMOGENESIS
CORP.
Condensed Consolidated
Statements of Cash Flows
(Unaudited)
|
|
|
Years Ended
June 30,
|
|
|
2010
|
|
2009
|
|
Cash flows from operating
activities:
|
|
|
|
|
Net loss
|
($5,193,000)
|
|
($8,550,000)
|
|
Adjustments to
reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
Depreciation and amortization
|
492,000
|
|
474,000
|
|
Stock
based compensation expense
|
518,000
|
|
479,000
|
|
Accretion of discount on short-term investments
|
(2,000)
|
|
(161,000)
|
|
Loss
on impairment of equipment
|
26,000
|
|
149,000
|
|
|
|
|
|
|
Net
change in operating assets and liabilities:
|
|
|
|
|
Accounts receivable
|
(1,797,000)
|
|
1,741,000
|
|
Inventories
|
34,000
|
|
(102,000)
|
|
Prepaid expenses and other current assets
|
361,000
|
|
(295,000)
|
|
Other assets
|
79,000
|
|
12,000
|
|
Accounts payable
|
602,000
|
|
(2,405,000)
|
|
Accrued payroll and related expenses
|
(572,000)
|
|
317,000
|
|
Deferred revenue
|
(132,000)
|
|
(562,000)
|
|
Other liabilities
|
1,156,000
|
|
107,000
|
|
Net
cash used in operating activities
|
(4,428,000)
|
|
(8,796,000)
|
|
|
|
|
|
|
Cash flows from investing
activities:
|
|
|
|
|
Purchase of
short-term investments
|
(6,741,000)
|
|
(25,957,000)
|
|
Maturities of
investments
|
15,719,000
|
|
38,045,000
|
|
Capital
expenditures
|
(470,000)
|
|
(1,008,000)
|
|
Net cash provided
by investing activities
|
8,508,000
|
|
11,080,000
|
|
|
|
|
|
|
Cash flows from financing
activities:
|
|
|
|
|
Payments on capital
lease obligations and note
payable
|
(4,000)
|
|
(13,000)
|
|
Net
cash used in financing activities
|
(4,000)
|
|
(13,000)
|
|
Net increase in cash and cash
equivalents
|
4,076,000
|
|
2,271,000
|
|
Cash and cash equivalents at
beginning of year
|
6,655,000
|
|
4,384,000
|
|
Cash and cash equivalents at end
of year
|
$10,731,000
|
|
$6,655,000
|
|
|
|
|
|
|
Supplemental non-cash financing
and investing
information
|
|
|
|
|
Transfer of
inventories to equipment
|
$165,000
|
|
--
|
|
Transfer of
equipment to receivables
|
$63,000
|
|
--
|
|
Transfer of
equipment to other assets
|
$137,000
|
|
$51,000
|
|
|
|
|
|
|
|
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in
developing and manufacturing automated blood processing systems and
disposable products that enable the manufacture, preservation and
delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, is used
by cord blood stem cell banks in more than 30 countries for
cryopreserving and archiving cord blood stem cell units for
transplant.
- AXP® AutoXpress™ Platform (AXP), a proprietary family of
automated devices that includes the AXP and the MXP™ MarrowXpress™
and companion sterile blood processing disposables for harvesting
stem cells in closed systems. The AXP device is used for the
processing of cord blood. The MXP is used for the preparation of
cell concentrates, including stem cells, from bone marrow aspirates
in the laboratory setting.
- The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is
designed for the preparation of cell concentrates, including stem
cells, from bone marrow aspirates.
- The CryoSeal® FS System, an automated device and companion
sterile blood processing disposable, is used to prepare fibrin
sealants from plasma in about an hour. The CryoSeal FS System is
approved in the U.S. for liver resection surgeries. The CryoSeal FS
System has received the CE-Mark which allows sales of the product
throughout the European community.
This press release contains forward-looking statements, and such
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
involve risks and uncertainties that could cause actual outcomes to
differ materially from those contemplated by the forward-looking
statements. Several factors, including timing of FDA approvals,
changes in customer forecasts, our failure to meet customers'
purchase order and quality requirements, supply shortages,
production delays, changes in the markets for customers' products,
introduction timing and acceptance of our new products scheduled
for fiscal years 2010 and 2011, and introduction of competitive
products and other factors beyond our control, could result in a
materially different revenue outcome and/or in our failure to
achieve the revenue levels we expect for fiscal 2010 and 2011.
A more complete description of these and other risks that
could cause actual events to differ from the outcomes predicted by
our forward-looking statements is set forth under the caption "Risk
Factors" in our annual report on Form 10-K and other reports we
file with the Securities and Exchange Commission from time to time,
and you should consider each of those factors when evaluating the
forward-looking statements.
ThermoGenesis Corp.
|
|
Web site:
http://www.thermogenesis.com
|
|
Contact: Investor
Relations
|
|
+1-916-858-5107, or
|
|
ir@thermogenesis.com
|
|
|
SOURCE ThermoGenesis Corp.
Copyright . 14 PR Newswire